An N, Li X, Shen M, Chen S L, Huang Z X
Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Zhonghua Yi Xue Za Zhi. 2018 Jan 30;98(5):365-369. doi: 10.3760/cma.j.issn.0376-2491.2018.05.010.
To investigate the clinical features and survival of multiple myeloma-associated amyloidosis patients. Twenty three multiple myeloma-associated amyloidosis patients were retrospectively analyzed from January 2009 to December 2016. The overall response rate(ORR)was 65.2% and the remission rate (sCR+ CR) was 21.7%. The median progression-free survival(PFS) was fourteen months(1-63), and the median overall survival(OS)was fifteen months(3-63). The early death rate (death rate within one year)was 33.3%. The median OS of patients(=9)with the performance status(PS) score >2 was seven months(1-15), and the median OS of patients(=14)with the PS score ≤2 was thirty months(10-63). There was a statistically significant difference in OS(<0.05); the median PFS and OS of the patients (=15) who responded to inductive treatment were seventeen months(2-63) and twenty four months (4-63)respectively, and the median PFS and OS of the patients (=8)who did not respond to inductive treatment were three months(1-8) and eleven months (3-15) respectively. There was a statistically significant difference in PFS and OS(<0.05). There was a statistically significant difference in PFS and OS between patients treated with remission (=5)and those who did not(=18) (<0.05). The multiple myeloma-associated amyloidosis patients had a high early death rate and short survival time. Early identification and effective treatment are the preconditions for improving the poor prognosis.
